Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
The global Blood Glucose Monitoring System Market, valued at US$15.16 billion in 2024, stood at US$16.46 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
According to Precedence Research, the global glucose biosensors market size will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91% from 2025 to ...
DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...
Investor's Business Daily on MSN
The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout
Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an ...
Zacks Investment Research on MSN
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
Insulet Corporation PODD reported third-quarter 2025 adjusted earnings per share (EPS) of $1.24, up 37.8% from the year-ago ...
If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...
Lead Plaintiff Deadline is December 26, 2025 NEW YORK, Nov. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback